At the 2024 American Thoracic Society conference, Surya Bhatt, MD, director of the Lung Imaging Lab at the University of Alabama of Birmingham discussed the NOTUS trial, a second phase three trial for treating COPD with type two inflammation using dupilumab, following the BOREAS trial.
Patients with pulmonary arterial hypertension with commercial insurance lose time from work to seek treatment.
An administration change in November could see the return of closed borders or increased protections for immigrants.
Undocumented individuals are ineligible for the Affordable Care Act (ACA) or federally funded Medicaid, but some states offer state-sponsored coverage for certain immigration statuses, such as Temporary Protected Status.
Immigrant children need a variety of resources when they come to the United States.
Speakers at the annual American Thoracic Society meeting discussed research looking at whether orangutan respiratory disease syndrome might have some of the same genetic causes as cystic fibrosis.
Discrimination, fear and lack of knowledge are just a few of the obstacles they face when trying to access healthcare.
Patients with more advanced pulmonary arterial hypertension incur higher costs overall, according to a poster at the annual ATS meeting.
The American Thoracic Society (ATS) has recommended moving to race-neutral equations for assessing what lung functions mean. A study presented at the ATS meeting this weekend projected how the new equation would affect disease classification, lung test standards for becoming a firefighter and VA disability benefits.
Results from a phase 2a study suggest that the benefits of Tezspire (tezepelumab) for people with chronic pulmonary obstructive disease may be limited to those with elevated blood eosinophil counts indicative of type 2 inflammation.
Results from the phase 3 NOTUS trial presented at the ATS meeting confirm benefits of Dupixent (dupilumab) among 20% to 40% of people with chronic obstructive pulmonary disease (COPD) who have evidence of type 2 inflammation.
Pamrevlumab is the third investigational agent to fail in a phase 3 trials. Researchers said It may be time to stop treating idiopathic pulmonary fibrosis as a single disease and treat subcategories organized by relevant biomarkers.
New study finds that daytime heat waves were associated with 19% higher odds of children’s asthma hospital visits. Longer heat waves doubled the odds of hospital visits.
Medicare patients under 65 who have pulmonary arterial hypertension require prolonged disability insurance and have found to have high healthcare costs, while further disparities are seen for those that face additional financial hardships, according to a poster at the annual ATS meeting.
Hundreds linked up to have their picture taken with Will Flanary, M.D., an ophthalmlogist in Portland, Oregon, and a hugely popular social media comedian after his talk yesterday during the open ceremony of the 2024 American Thoracic Society (ATS) International Conference in San Diego .
William Flanary, M.D.., has a huge social media following as Dr. Glaucomflecken, a character he created on Twitter when he was an ophthalmology resident in Iowa. More than 13,400 people have registered to attend the American Thoracic Society (ATS) International Conference, which is being held this weekend at the San Diego Convention Center.
Debra Boyer, M.D., M.H.P.E., discussed the program of the 2024 American Thoracic Society International Conference in San Diego and the limits of artificial intelligence.
